الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> PD-1/PD-L1 interaction>>PD-1/PD-L1-IN 7

PD-1/PD-L1-IN 7 (Synonyms: PD-1/PD-L1-IN 7)

رقم الكتالوجGC62658

PD-1 / PD-L1-IN 7 (PD-1 / PD-L1-IN 7) هو مثبط تفاعل بروتين / بروتين PD-1 / PD-L1 بشري مع IC 50 من 0.213 نانومتر.

Products are for research use only. Not for human use. We do not sell to patients.

PD-1/PD-L1-IN 7 التركيب الكيميائي

Cas No.: 2374856-75-2

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
657٫00
متوفر
5 mg
432٫00
متوفر
10 mg
720٫00
متوفر
25 mg
1485٫00
متوفر
50 mg
2295٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PD-1/PD-L1-IN 7 is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 has anticancer and antiviral functions[1].

PD-1/PD-L1-IN 7 (compound 139) enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. PD-1/PD-L1-IN 7 also enhances the frequency of GrB+ cells among HBV-specific CD8+ and CD4+ T cells. The ability of PD-1/PD-L1-IN 7 to enhance the antiviral functions of HBV-specific CD8+ and CD4+ T cells in vitro is comparable to those of Durvalumab[1].

PD-1/PD-L1-IN 7 (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. PD-1/PD-L1-IN 7 significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model[1].

[1]. Evangelos Aktoudianakis, et al. Pd-1/pd-l1 inhibitors. WO2019160882A1.

مراجعات

Review for PD-1/PD-L1-IN 7

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD-1/PD-L1-IN 7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.